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ABSTRAK 
 
Kajian Pithecellobium jiringa (Jack) Prain Ke Atas Laluan Mekanistik 
Karsinogenesis dan Angiogenesis 
 
Dalam kajian ini, potensi kulit buah P. jiringa sebagai anti-tumor telah 
diselidik. Satu siri penyelidikan untuk menilai kesan anti-tumor dan komponen-
komponen yang memainkan peranan dan sasaran biologikal yang menyumbang 
kepada kesan anti-tumor telah dijalankan. Dalam bahagian pertama kajian ini, satu 
siri pengekstrakan kulit buah P. jiringa dari pelarut 100% etanol (EtOH), 50% etanol 
(EW), 50% metanol (MW), 100% metanol (MeOH) dan 100% air (Wa) telah 
dikembangkan melalui teknik maserasi. Ekstrak-ekstrak tersebut telah memberi 
kesan sitostatik yang kuat kepada sel-sel endothelium pembuluh umbilikal (HUVEC) 
(IC50 0.60 ± 0.15 µg/ml dan 3.01± 0.05 µg/ml untuk EtOH and EW) dan aktiviti 
sitotoksik terpilih yang kuat ke atas sel-sel kanser kolorektal (HCT 116) (IC50 5.54 ± 
0.13 µg/ml dan 12.63 ± 0.17 µg/ml untuk EtOH and EW). Kajian anti-kanser in vitro 
ke atas sel-sel HCT 116 telah menyebabkan kematian sel melalui laluan ekstrinsik. 
Ekstrak-ekstrak EW dan EtOH didapati menyebabkan gangguan pada penghijrahan 
dan pembentukan tiub endotelium di dalam sel-sel HUVEC. Ekstrak-ekstrak ini juga 
telah menyebabkan perencatan angiogenesis di dalam ujian tisu terasing dan 
merencat pengungkapan VEGF yang merupakan penanda angiogenesis utama. 
Aktiviti anti-angiogenic juga telah dicerap secara in vivo di dalam embrio telur ayam 
yang subur. Kedua-dua ekstrak EW dan EtOH menunjukkan kelimpahan unsur-unsur 
fenolik yang memberi sifat antioksidan yang kuat. Sifat yang kedua mungkin faktor 
utama menyumbang kepada aktiviti anti-angiogenic yang dicerap. Hasil keputusan 
22 
 
daripada kajian-kajian ini mencadangkan bahawa ekstrak EW dan EtOH mungkin 
berguna untuk terapi kanser terutama sekali terhadap tumor yang bergantung tinggi 
kepada angiogenesis seperti kanser kolorektal.  
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STUDY OF PITHECELLOBIUM JIRINGA (JACK) PRAIN ON 
CARCINOGENESIS AND ANGIOGENESIS MECHANISTIC 
PATHWAY 
 
ABSTRACT 
 
In this work, the anti-tumour potential of P. jiringa fruit rind was investigated. 
An array of studies was carried out to evaluate its anti-tumour effect and 
characterised the components at play and the biological target(s) that contribute to 
the anti-tumour effect. In the first part of this work, a series of solvent extract(s) of 
the P. jiringa fruit rind namely 100% ethanol (EtOH), 50% ethanol (EW), 50% 
methanol (MW), 100% methanol (MeOH) and 100% water (Wa) was developed via 
maceration technique. The extracts gave strong cytostatic response on human 
umbilical vein endothelial cells (HUVEC) (IC50 0.60 ± 0.15 µg/ml and 3.01± 0.05 
µg/ml for EtOH and EW respectively) and strong selective cytotoxic activity on 
colorectal cancer cells (HCT 116) (IC50 5.54 ± 0.13 µg/ml and 12.63 ± 0.17 µg/ml 
for EtOH and EW respectively) The in vitro anti-cancer study on HCT 116 cells 
showed that both EtOH and EW extracts caused cell death via extrinsic pathway. In 
the HUVEC cells we found that both EW and EtOH disrupted cell migration and 
endothelial tube formation. The extracts caused marked inhibition of angiogenesis in 
isolated tissue assay and inhibited the expression of VEGF which is the key marker 
of angiogenesis. The anti-angiogenic activity was also observed in vivo in fertilised 
chicken egg embryo. Both EW and EtOH showed abundance of phenolic compounds 
giving rise to strong antioxidant property. The latter may be the key factor that 
24 
 
contributes to the anti-angiogenic activity observed. The result of this study suggests 
that EW and EtOH extracts may be useful in cancer therapy particularly towards the 
highly angiogenic dependent tumours such as colorectal cancer. 
 
1 
 
CHAPTER 1: INTRODUCTION 
 
1.1 Cancer 
Cancer refers to malignant diseases affecting various parts of the body. This 
disease is characterised by rapid, uncontrolled abnormal cell formation leading to 
tumour formation which may further proliferate throughout the body (Vanhoecke et 
al. 2005). Cancer has become a major public health concern in most regions of the 
world. Cancer statistics comprised cases reported on both men and women in 
developed and developing regions shows that incidence rates of cancers in developed 
regions are higher than in developing regions; however, the mortality rates are 
typically higher in developing regions (Parkin et al. 2005).  
In 2002, the number of new cancer cases reported was 10.9 million, with 6.7 
million deaths and estimation of 24.6 million persons living with cancer worldwide 
(Parkin et al. 2005). Among all cancers, the major five according to the highest 
incidence rates recorded were lung cancer with 1.35 million cases, breast cancer of 
1.15 million cases, colorectal cancer with 1.02 million cases, stomach cancer of 
934,000 cases and liver cancer of 626,000 cases. In addition, lung cancer was also 
reported as the highest cancer deaths with 1.18 million deaths, stomach cancer 
700,000 deaths, liver cancer 598,000 deaths, colorectal cancer 529,000 deaths and 
411,000 deaths related to breast cancer (Parkin et al. 2005).  
Higher cancer incidence in developed regions is most likely attributed to the 
lifestyle and the most common diagnosed cancers being colorectal, breast and 
prostate (Parkin et al. 2005; Kintzios & Barberaki 2004). However, in developing 
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regions, commonly diagnosed cancers are liver, stomach and oesophagus. Developed 
countries show better prognosis than developing countries. Apparently, early 
detection of cancers and quality treatment both contribute to good prognosis and 
higher survival rates (Parkin et al. 2005). 
 
1.1.1 Causes of Cancer 
The main cause of cancer is still inconclusive; however factors such as 
exposure to environmental pollution, poor diet, hereditary factors as well as viral 
infection have been implicated (Kintzios & Barberaki 2004). Nevertheless, in 
cancers such as breast and prostate which are regulated by hormones, the influence 
of genetics plays a greater role. The responsible genes include proto-oncogenes and 
tumour suppressor genes. The proto-oncogenes stimulate cancerous cells growth 
whereby tumour suppressor genes serve to prevent cells growth (Kintzios & 
Barberaki 2004).  
Under normal setting, balance synchronisation of both genes contribute to 
normal cell proliferation but due to mutation, the proto-oncogenes cause excessive 
cells division while tumour suppressor genes are unable to impede the cells division 
(Kintzios & Barberaki 2004). Examples of tumour suppressor molecules include 
pRB, p15, p16, p21 and p53; examples of oncogenes include Erb-B, Ki-ras and c-
myc (Bergers & Benjamin 2003).  
Environmental factors include groups that may pose as carcinogens due to 
prolong exposure to certain chemical substances, poor diet, ionising radiation and 
pathogens (Kintzios & Barberaki 2004).  
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Cancer is also attributed by viruses and bacteria. Infection by viruses and 
bacteria contributes to 1.2 million cases of malignancies per year (Balkwill & 
Mantovani 2001; Kuper, Adami & Trichopoulos 2000) often by human 
papillomaviruses (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV) and 
Epstein-Barr virus (EBV). These viruses contribute to arising of cervical cancer, 
hepatocellular carcinoma (HCC), and oral cancer and lymphoproliferative disorders 
(Karin & Greten 2005). These viruses work by inhibiting the actions of tumour 
suppressor gene and often cause inflammation (Karin & Greten 2005; Balkwill & 
Mantovani 2001). It has been shown that inflammation is strongly related to onset of 
neoplasm (Philip, Rowley & Schreiber 2004). However, a noteworthy fact is that not 
all microorganisms work by the mentioned mechanisms. Helicobacter pylori which 
is the main cause of gastric cancer, do not carry oncogenes nor does it inhibit the 
action of tumour suppressor proteins (Karin & Greten 2005).  
 
1.1.2 Cancer Pathology 
In the occurrence of cancerous and malignant cells, there are six vital 
alterations that take place. They are self-sufficiency in growth signals, insensitivity to 
growth-inhibitory signals, evasion of programmed cell death, limitless replicative 
potential, sustained angiogenesis as well as tissue invasion and metastasis (Hanahan 
& Weinberg 2000). 
Most cancers are of epithelial origin such as mammary gland, bronchi, colon, 
prostate and skin. As growth of tumour progress, the surrounding normal host 
becomes part of the tumour forming a micro-ecosystem (Vanhoecke et al. 2005). The 
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tumour hosts cells such as fibroblasts, immune cells, platelets and extracellular 
matrix which also contain regulators for cancer cell growth, differentiation, invasion 
and survival. The heterogeneity of the tumour highlights the importance of multi-
targeted therapy that aims for cancer cells as well as the surrounding normal host 
tissues (Vanhoecke et al. 2005). 
Genetic mutations of cells typically leads to functional alterations (Vanhoecke 
et al. 2005). Due to the mutations which occur at typically fast rate, the cells 
proliferate to form group of cells with normal appearance known as hyperplasia. 
Cells in the state of hyperplasia then undergo further mutation to form abnormal 
group of cells known as dysplasia. Dysplasia can endure additional mutation leading 
to tumour formation (Kintzios & Barberaki 2004). Malignant tumours refer to 
tumour cells which remain localized in its original place while metastasis refers to 
formation of new tumours via invasion and spreading of cancer cells.  
There are two key properties which are vital for cancer cells to remain viable. 
One of the most important features is the ability to divide infinitely which is non-
existent in normal cells. The second characteristic is the ability of the cell to grow 
without requiring attachment to another tissue or cells (Kintzios & Barberaki 2004). 
While normal cells adhere to each other and extracellular matrix, cancer cells do not 
adhere but they have the ability to migrate including invading other tissues and form 
masses of cells. Though such malignant cells are small in number, they eventually 
will turn more aggressive over time (Kintzios & Barberaki 2004; Bergers & 
Benjamin 2003).  
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There are three mechanistic phases governing carcinogenesis, namely 
initiation, promotion and progression (Karin & Greten 2005). In tumour initiation 
which involves stable genomic alterations, chemical or physical carcinogens cause 
mutation on DNA of cells; thus triggering the activation of oncogenes and or 
inactivation of tumour suppressor genes. Tumour promotion involves proliferation of 
genetically altered cells; there is occurrence of clonal expansion of initiated cells 
which is due to increased cell proliferation and/or reduced cell death (Karin & Greten 
2005). Example of tumour growth promoter include cytokines such as interleukin-1 
(IL-1), IL-6 and tumour-necrosis factor (Karin & Greten 2005; Harris 2002). 
In cancerous cells, activation of signal transduction pathways in turn triggers 
activation of membrane bound receptors by autocrine, paracrine and endocrine 
growth factors. Upon activation of these key factors, cancerous cells are able to 
proliferate and grow. In contrast to normal cells, signal transduction pathways in 
cancer cells often gets mutated or overexpressed which leads to activation of 
elements such as tyrosine kinases growth factor receptor (Lobbezoo, Giaccone & van 
Kalken 2003). Cancerous cells have the ability to produce their own growth signals 
with minimal dependence on stimulation from normal tissues environment (Hanahan 
& Weinberg 2000). Overexpression of growth receptors may elevate the 
responsiveness of the cancer cells such as overexpression of HER/neu receptor in 
stomach and mammary carcinomas (Slamon et al. 1987). Expression of signal 
transduction pathways in tumour cells encouraged the search for drug molecules to 
act on specific proteins in the pathways. These molecules have been referred to as 
signal transduction modulators (STMs). Such molecules interact within the pathways 
by blocking cell surface receptors, impeding the tyrosine kinases growth factor 
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receptor, or elicit inhibition on mitogen-activated protein kinases. Example of STMs 
are the FDA approved anti-cancer drugs; trastuzumab and imatinib (Lobbezoo, 
Giaccone & van Kalken 2003).  
 
1.2 Angiogenesis and Cancer 
Angiogenesis is the formation of new blood vessels sprouting from existing 
vascularisation (Kusaka et al. 1991; Folkman 1990; Rosen 2002). The process can 
also occur during oxygen and nutrient deprivation in normal tissues and arise as a 
result of metabolic tissues, new organ and embryogenesis development, wound 
healing and reproductive functions. In the early 1970s it was noted that solid tumours 
appear to be highly vascularised (Folkman 1971).  
It was then established that all solid tumours are dependent on the angiogenesis 
process in order for the tumour to grow larger and spread to other parts of the body 
(Folkman 1990; Folkman 1971). The process also takes place in some pathological 
conditions such as inflammatory diseases such as rheumatoid arthritis, 
atherosclerosis, proliferative retinopathies, psoriasis as well as cancers (Rosen 2002).  
 
1.2.1 The Progression of Angiogenesis Cascade 
The angiogenesis process is constructed by a series of sequential steps (Eccles 
et al. 2009; Auerbach et al. 2003). Firstly, the vascular basement membrane of 
existing blood vessels as well as extracellular matrix are both degraded in order to 
permit migration of underlying endothelial cells into the perivascular space towards 
chemotactic angiogenic stimuli (Eccles, Box & Court 2005). The endothelial cells 
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then start to proliferate leading to massive sprouting enhancing migration towards the 
perivascular space, to form migration column (Fischer, Schneider & Carmeliet 
2006).  
The migration columns then direct cells to differentiation whereby the 
endothelial cells change shape and begin to adhere to each other and cells get 
organised into forming lumen-capillary tubes with tight junctions and deposition of 
new basement membrane (Eccles, Box & Court 2005). Endothelial cells within the 
vascular wall that constantly undergoes proliferation result in larger diameter of the 
blood vessel. Thus, it attracts perivascular cells which in turn produce a vascular 
basal lamina around the new blood vessels (Bergers & Benjamin 2003; Mojzis et al. 
2008; Fischer, Schneider & Carmeliet 2006). The angiogenesis process is as shown 
in Figure 1.1. 
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Figure 1.1 The angiogenesis cascade. (a) Blood vessels emerge from existing 
vasculature, (b) pericytes (in green) detach, blood vessels dilate before basement 
membrane and extracellular matrix gets degraded (c) which allows endothelial cells 
to migrate into perivascular space towards angiogenic stimuli, (d) then endothelial 
cells proliferate, following one another, lead by pericytes, (e) endothelial cells adhere 
to each other forming a lumen; formation of basement membrane and attachment of 
pericytes. The sprouting of blood vessels will enable formation of new circulatory 
systems; however, limited information is present on this fusion mechanism. Adapted 
from (Bergers & Benjamin 2003). 
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1.2.2 Role of Angiogenesis Inhibitors in Cancer Therapy  
1.2.2.1 Current Methods in Cancer Therapy 
In treating cancers, there are two methods which are commonly used. 
Conventional treatment which includes surgery, radiotherapy and chemotherapy 
(Kintzios & Barberaki 2004). Surgery is the preferred method of cancer therapy 
especially when the cancerous tissue is still localised and has not metastasized. 
However, this method may cause scarring and also injure healthy organs. 
Furthermore remnants of neoplastic tissues may still be present (Kintzios & 
Barberaki 2004). In radiation therapy, the cancerous cells are exposed to ionising 
waves which causes DNA fragmentation leading to apoptotic cell death. However, 
the presence of radiosensitive cancer cells often leads to treatment failure. Then, 
immunotherapy and inhibition of angiogenesis, are classified as advanced cancer 
treatment methods (Kintzios & Barberaki 2004; Pesenti et al. 1992). 
Chemotherapy employs cytotoxic agents that either targets the DNA of cancer 
cells leading to their damage or specific metabolic pathways that are crucial for the 
cell survival. Treatment of chemotherapy can be generalised into various groups 
namely anti-metabolites, alkylating agents, topoisomerase inhibitors, antibiotics and 
anthracyclines (Kintzios & Barberaki 2004). Since cancerous cells have the ability to 
divide infinitely, they require continuous synthesis of genetic material (DNA). As 
such, chemotherapy agents target DNA in the effort to impede the cancerous cells’ 
growth (Siddik 2005). Chemotherapy agents kill cancerous cells by interrupting 
DNA and its replication (Alakananda & Soumya 2011) which inhibit DNA synthesis, 
hence affecting RNA and proteins productions (Siddik 2005).  
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Among all chemotherapy drugs, alkylating agents have been identified as the 
most effective anti-cancer agent used (Alakananda & Soumya 2011). Alkylating 
agent refers to compounds which can replace hydrogen atom in another molecule by 
an alkyl radical through electrophilic attack (Warwick 1963). Any distortions and 
unwinding in DNA caused by interaction between the DNA with alkylating agents 
will affect the cell cycle development, thereby blocking new DNA replications on the 
damaged DNA template or prevent damaged chromosomes to be passed on to 
daughter cells. The action exerted by alkylating agents however often cause side 
effects due to poor selectivity (Siddik 2005).  
There are five classes of alkylating agents; nitrogen mustards, aziridines, alkyl 
sulphonates, nitrosoureas and mechanistically distinct platinum-containing drugs. 
Generally, alkylating agents due to their chemical reactivity, form covalent linkages 
at nucleophilic sites on different DNA bases to induce cross-linkages. While 
traditional alkylators interact with DNA by guanine bases, the platinum-containing 
drug form covalent bonding between adenine and or guanine bases via the platinum 
atom (Siddik 2005). The platinum-containing drug is considered as one example of 
effective anti-cancer treatment due to its positive response either as single drug or in 
combination with other standard chemotherapy regimens (Siddik 2005; Alakananda 
& Soumya 2011). Such example centres on cisplatin. The anti-tumour effect exerted 
by cisplatin is contributed by its interaction with chromosomal DNA, which causes 
DNA damage. Like other chemotherapeutic drugs, cisplatin may likely induce 
apoptosis, occurring via extrinsic or intrinsic pathways (Alakananda & Soumya 
2011).  
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Recent arsenals in cancer therapy are the monoclonal antibodies which target 
key components of cancer cell receptors and cytokines (Ferrara, Hillan & Novotny 
2005; Oldham 1983). In treating cancers, the lack of specificity of the drug to cancer 
cells is one of the major drawbacks. However, since the introduction of monoclonal 
antibodies which involves selection of single cells and clonal expansion of a single 
hybrid between antibodies-forming cell and myeloma cell (Oldham 1983; Hudis 
2007), there have been clinically-proven positive responses in patients suffering from 
metastatic breast (Slamon et al. 2001) and colorectal cancer (Ferrara, Hillan & 
Novotny 2005).  
The mechanisms by which monoclonal antibodies work to affect the tumour 
cells vary according to each type. Most monoclonal antibodies interact with the 
immune system through antibody-dependent cellular cytotoxicity (ADCC) which 
occurs as the antibodies bind to antigens on tumour cells and antibody Fc domains 
connects with Fc receptors (FcR) on the immune effector cells’ surface. The Fc-
receptors interactions have been shown to cause substantial anti-tumour activity 
(Adams & Weiner 2005). Example of such monoclonal antibody is the FDA-
approved trastuzumab (Herceptin, Genentech), the first humanised monoclonal 
antibody which targets HER2 gene in metastatic breast cancer patients (Slamon et al. 
2001). The antibody has shown significant survival percentage in patients 
administered with the antibody alone or in combination with standard chemotherapy 
(Slamon et al. 2001; Baselga & Albanell 2001).  
Monoclonal antibody may also interact with the immune system through 
complement-dependent cytotoxicity (CDC); binding of monoclonal antibodies to 
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antigen on the cell surface causes exposure of binding sites on the antibodies which 
lead to discharge of chemotactic factors and formation of membrane attack complex 
(Adams & Weiner 2005). Example of such monoclonal antibody is the murine-
human chimeric rituximab (Rituxan, Biogen Idec/Genentech) targeting CD20 antigen 
in treating lymphomas (Adams & Weiner 2005).  
Apart from such mechanisms, targeting ligands initiating signalling through 
receptors has also become of great interest. An example of a monoclonal antibody 
depicting such action is bevacizumab (Avastin, Genentech/Roche) which primarily 
targets to block the binding of VEGF-A (an isoform of VEGF) to their receptors on 
the vascular endothelium (Ferrara, Hillan & Novotny 2005). As VEGF has been 
identified as the responsible stimulator for new blood vessels growth, thus 
incorporating bevacizumab in standard chemotherapy regimen for metastatic 
colorectal cancer has shown improved response rates and survival (Ferrara, Hillan & 
Novotny 2005; Adams & Weiner 2005; Mukherji 2010).  
Endothelial cells in tumour bed tend to be more susceptible to cytotoxic agents 
due to their high proliferation rate. In addition, in comparison to cancerous cells, 
endothelial cells are genetically stable as they do not undergo mutations such as p53 
mutation and hence prone to apoptotic effects of the cytotoxic agents. Thus, these 
features of endothelial cells make a compelling target for anti-angiogenesis treatment 
(Folkman 2003). As such, cytotoxic agents pose as candidate as anti-angiogenic 
agent on top of their potent activity in causing death of cancerous cells. Paclitaxel, an 
anti-cancer drug has been shown to inhibit proliferation of endothelial cells as well as 
cells migration and invasiveness dose-dependently in both in vitro and in vivo. 
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Cytotoxic agents cause apoptosis on endothelial cells which then direct apoptosis on 
cancerous cells thus causing the inhibition of cancerous cells (Folkman 2003).  
In demonstrating cytotoxic drug as anti-angiogenic agent, it is best viewed by 
an alternative administration to maximum tolerated dose (MTD) known as 
metronomic therapy (Browder et al. 2000; Kerbel & Kamen 2004). Conventional 
chemotherapy is usually administered at MTD which then need breaks between 
treatments. During the breaks, endothelial cells were found to proliferate and this 
contributed to recurrence of the tumour growth (Folkman 2003). Opposing to 
conventional chemotherapy which suppressed tumour growth but found recurrence 
of tumour growth leading to drug resistant and cells deaths; metronomic anti-
angiogenic scheduling therapy has shown that the drug inhibited significant tumour 
growth (Kerbel & Kamen 2004). Addition of pure anti-angiogenesis inhibitor with 
the initial chemotherapy showed complete deterioration of the tumour and high 
percentage of survival (Browder et al. 2000; Folkman 2003). This has since 
illustrated the endothelial-dependent on cytotoxic agent and shown potencies of 
cytotoxic agent as anti-angiogenic agent (Folkman 2003).  
Since the introduction of the hypothesis focusing on tumour is angiogenesis-
dependent by Folkman in 1971 (Folkman 1971), massive research and development 
on angiogenesis as well as studies on its pro- and anti-molecules has sparked interest 
of researchers in angiogenesis-related field worldwide. Extensive studies have been 
carried out to develop therapeutic strategies such as in stimulating revascularisation 
of ischaemic tissues as well as development of anti-angiogenesis agent to be used in 
diseases such as cancers and inflammation (Fischer, Schneider & Carmeliet 2006).  
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Examples of positive outcome spring forth from anti-angiogenic studies is the 
FDA-approved bevacizumab (Avastin, Genentech/Roche) for colorectal, breast and 
lung cancer treatment in combination with conventional chemotherapy. Avastin 
works by blocking the VEGF expression, thus inhibiting angiogenesis (Fischer, 
Schneider & Carmeliet 2006; Ferrara, Hillan & Novotny 2005).  
Conventional chemotherapy drug is usually administered at maximum dose, 
which initially causes inhibition of cancerous cells. However, drug-free interval 
following treatment cause massive proliferation of the endothelial cells that hosts the 
cancerous cells. Thus, recurrence of tumour growth resumes and speeds up to cause 
death due to drug-resistance of the tumour. Anti-angiogenic treatment however 
overcomes this setback by administering low doses without drug-free interval, hence 
the tumours are significantly inhibited and contributes to higher percentage of 
survival (Browder et al. 2000).  
Anti-angiogenesis has the advantage in succeeding conventional chemotherapy 
as administration of drugs must cross microvascular endothelium before reaching the 
tumour cells. Since endothelial are of low probability to mutate and are genetically 
stable, principally they are readily susceptible to apoptosis effects of the drug. Anti-
angiogenic drug then targets endothelial cells before acting on tumour cells (Folkman 
2003).  
Although given all the advantages of anti-angiogenesis treatment, some 
disadvantages may emerge. Clinical trials of pro-angiogenic molecules of VEGF and 
FGF failed to meet initial expected results; responsibilities of these unexpected 
outcome were pointed to poor delivery strategies and the uncontrolled regulation of 
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functional vessel growth (Fischer, Schneider & Carmeliet 2006). Then, it is 
speculated that long duration of conventional chemotherapy combined with anti-
angiogenic agent may pose adverse toxic effect (Mukherjee et al. 2004). 
Nevertheless, the toxicity effect of anti-angiogenic agent can be avoided by adopting 
promising approach such as biologically active dose that will model as acceptable 
toxicity profiles (Mukherjee et al. 2004; Mendel et al. 2003). Anti-angiogenic agent 
may also play a role in normal growth of humans as well as possibilities in disturbing 
pregnancies as shown by studies on teratogenic drug. However, these drawbacks can 
be avoided so long that the necessary angiogenesis process are not disrupted 
(D'Amato et al. 1994).  
In the advancement of anti-angiogenesis therapy, therapeutics agents targeting 
to directly attack tumour blood vessels rather than to inhibit the tumour 
vascularisation has emerged as one of the latest approach (Frankel et al. 2011). Such 
approach utilises antagonist effect against expression of some receptors on the 
endothelial cells lining the tumour vasculature which generates overexpression of 
tumour endothelial markers (TEMs) such as TEM-8 and capillary morphogenesis 
gene-2 (CMG-2) (Cryan & Rogers 2011) which are known receptors for mediating 
access of anthrax toxin into host cells (Werner, Kowalczyk & Faundez 2006) and are 
highly specific to tumour angiogenesis (Maurya et al. 2011). Since the expression of 
TEMs level up during the cascades of angiogenesis, this points to possibilities in 
selectively targeting the tumour endothelium as an approach of anti-angiogenic 
therapy (Cryan & Rogers 2011; Werner, Kowalczyk & Faundez 2006). Previous 
studies showed anti-angiogenic potential of CMG-2 and TEM-8 whereby reduction 
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of their expressions inhibited endothelial proliferation, migration and differentiation 
(Reeves et al. 2009; Cryan & Rogers 2011).  
 
1.2.2.2 Angiogenic Switch 
As initially proposed by Folkman, tumour growth and metastasis are 
angiogenesis-dependent (Folkman 1971). Thus targeting angiogenesis inhibition may 
well contribute to blocking of tumour growth. As such, the proposed idea has since 
generated the search for pro- and anti-angiogenic molecules (Carmeliet & Jain 2000).  
In every normal tissue, physiological changes occur as a result of balance 
between pro- and anti-angiogenic factors. In response to the physiological stimuli, 
endothelial cells react by its dividing ability. Such mechanism is corresponding to 
wound healing. However, the physiological stimuli may also become extremely 
excessive which causes imbalance between stimulators and inhibitors, thus resulting 
in an angiogenesis switch (Mojzis et al. 2008). The switch is “off” upon balancing 
between stimulators and inhibitors molecules and “on” when the stimulators 
outweighs the inhibitors (Carmeliet & Jain 2000). Table 1.1 depicts some stimulators 
and inhibitors responsible for the angiogenic switch.  
The signals triggering the switch include environmental and genetic changes. 
Such changes are hypoxia, pH variation, metabolic stress, cytokines from 
inflammatory response as well as genetic mutations potentiated by up-regulating of 
oncogenes such as Src and Ras and down-regulation of tumour suppressor gene such 
as p53 (Pang & Poon 2006; Carmeliet & Jain 2000). As a consequence, the switch 
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gives rise to various disorders such as cancer, infectious diseases, atherosclerosis, 
arthritis, diabetes, obesity and inflammation diseases (Mojzis et al. 2008).  
The introduction of oncogenes into tumours has been shown to rapidly cause 
the angiogenic switch. This is supported by the observation of transfected human 
non-angiogenic osteosarcoma with Ras oncogene had led to neovascularisation in 
two weeks (Folkman 2003). Activity of some hormones such as androgen, 
progesterone and oestrogens may also promote angiogenesis through carcinogenesis 
and tumour progression in hormone-dependent cancers such as prostate and breast 
cancers (Pang & Poon 2006). Thus, it is noteworthy to acknowledge the 
contributions of the factors in inducing the angiogenic switch are tumour-type 
dependent. Their contributions are also likely to change with the tumour growth, 
progression and degeneration (Carmeliet & Jain 2000). 
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Table 1.1 Examples of some stimulators and inhibitors of angiogenesis 
 
Stimulators Function Inhibitors Function 
VEGF Stimulate angiogenesis and 
vasculogenesis, induces permeability 
and leukocyte adhesion 
Angiostatin and related 
plasminogen  
Suppress tumour angiogenesis 
TGF-β1, endoglin, 
TGF-β receptors 
Stimulate extracellular matrix 
production 
Endostatin Inhibit endothelial cell survival and 
migration 
Plasminogen 
activators, MMPs 
Remodel matrix, release and activate 
growth factors 
IFN-α, -β, -γ; IL-4, -12, -18 Inhibit endothelial migration and 
downregulation of bFGF 
PDGF-BB and 
receptors 
Recruit smooth muscle cells Prothrombin  Suppress endothelial growth 
FGF, HGF, MCP-1 Stimulate angiogenesis/arteriogenesis Platelet factor-4 Inhibit binding of bFGF and VEGF 
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1.2.2.3 VEGF and Its Role in Angiogenesis 
Many proteins are associated with regulating the process of angiogenesis. 
Vascular endothelial growth factor (VEGF) is a protein that stimulates 
vasculogenesis and angiogenesis (Kondo et al. 2002). VEGF is also known as 
VEGF-A. The VEGF family, in addition to VEGF-A also comprise of VEGF-B, -C 
and -D and placental growth factor (PGF) (Ferrara, Hillan & Novotny 2005; Rakic et 
al. 2003). Regulatory responses of PIGF and its receptor Flt1 (also known as VEGF-
R1) on angiogenesis cascade causes loss of VEGF-R1 thwarted angiogenic process 
as well as vascular leakage in cancer, ischaemia and wound healing (Rakic et al. 
2003).  
VEGF which is a secreted angiogenic mitogen targeting specifically vascular 
endothelial cells has been identified as a potent angiogenic factor (Breier et al. 1992). 
Normally, VEGF helps to stabilise oxygen supply when normal circulation is not 
enough. VEGF is also responsible in the formation of new blood vessels (Kondo et 
al. 2002). Apart from stimulating endothelial cell growth and differentiation, VEGF 
is also noted for its capability in inducing vascular permeability and in attracting 
monocytes thus enhancing their migration in vitro (Breier et al. 1992). However, 
overexpression of VEGF contributes to diseases such as cancers. Typically, cancer 
tumour cannot grow without adequate blood supply, so in the case of overexpression 
of VEGF, the tumour will grow and metastasize (Kondo et al. 2002).  
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1.2.2.4 Role of Hypoxia in Angiogenesis 
Hypoxia is defined as insufficient oxygen level which is needed in maintaining 
normal cellular functions (Harris 2002). Hypoxic conditions can trigger angiogenesis 
(Bergers & Benjamin 2003). Hypoxia takes place during acute and chronic vascular 
disease, pulmonary disease as well as cancers. Acute hypoxia is when formation of 
new blood vessels of the tumours is abnormal causing insufficient and inefficient 
blood flow and therefore the needed oxygen supply. Chronic hypoxia on the other 
hand occurs when the oxygen level is not sufficient to accommodate the massive 
formation of new blood vessels from uncontrolled proliferation (Harris 2002).  
Hypoxia induces transcription programme leading to aggressive tumour 
phenotype. Hypoxic tumours occur when the new blood vessels formed are 
abnormal, causing deprivation of blood flow. Hypoxia is toxic to both normal and 
cancerous cells but under genetic changes, these cells are able to survive and thus 
proliferation continues (Bergers & Benjamin 2003). Their proliferation thus cause 
the cells to become more invasive and lead to emergence of malignant phenotype of 
tumours (Harris 2002).  
Hypoxia has long been regarded as one of the key features contributing to 
tumour, which also makes the cells to become aggressively resistant to apoptosis as 
well as to conventional cancer treatment such as radiation and chemotherapy (Melillo 
2006). Due to hypoxic conditions, there arise several biological responses which are 
alteration of aerobic to anaerobic metabolism, induction of erythropoietin (EPO) in 
renal cells, induction of tyrosine hydroxylase synthesis in neural cells and production 
of growth factor that stimulates angiogenesis (Harris 2002).  
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Transcription factor hypoxia-inducible factor 1 (HIF-1) is the responsible key 
player in stimulating the transcriptional response of cells to insufficient oxygen 
supply (Melillo 2006). HIF-1 is made up of hypoxic factor (HIF-1α) and 
constitutively expressed aryl hydrocarbon receptor nuclear translocator, ARNT (also 
known as HIF-1β) composing a heterodimer. Adhering of HIF-1 in the absence of 
oxygen to hypoxia-response elements such as DNA triggers expression of several 
pro-angiogenic factors such as vascular endothelial growth factor (VEGF), fibroblast 
growth factor-3 (FGF) and platelet-derived growth factor-B (PDGF) (Harris 2002). 
HIF-1 is essential for normal embryogenesis and tumourigenesis (Ryan, Lo & 
Johnson 1998).  
Genes induced by hypoxia regulate several biological processes such as cell 
proliferation, angiogenesis, metabolism, apoptosis, immortalisation and migration. 
Production of growth factors such as transforming growth factor-β (TGF-β) and 
PDGF upon induction by hypoxia, promote cell proliferation (Bergers & Benjamin 
2003; Harris 2002). The imperative effect of HIF-1α is prominent, as its deletion 
may inhibit cell growth and thus angiogenesis. Furthermore, activation of VEGF 
transcription and one of its receptors, VEGF receptor 1 (VEGF-R1) directly regulates 
endothelial cell growth proliferation and thus blood vessels formation. Activation of 
HIF-1 also cause lower expression of anti-angiogenic proteins such as 
thrombospondin-1 and -2 (Harris 2002).  
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1.3 Plants with High Antioxidant Property and Their Anti-cancer Property 
For centuries, humans have been utilising natural products particularly plants 
in treating various ailments. In relieving certain illnesses, combination of medicinal 
herbs is often adopted. In many parts of the world, this traditional medication system 
is still much appreciated and practiced; sometimes it is the preferred medication 
option (Cai et al. 2004). Plants and natural products have such immense effect in 
treating varieties of diseases such as cancers, in fact around 74% of anti-cancer drugs 
used today originates from natural products (Lopes et al. 2009).  
Plants consist of various phytochemical groups which have valuable 
pharmaceutical applications. Secondary metabolites which refer to compounds 
consisting of various chemical groups such as phenolics, flavonoids, alkaloids, 
terpenoids, glycosides, lipids, organic acids and aromatic compounds are among the 
active phytochemicals occurring abundantly in plants (Kintzios & Barberaki 2004).  
Secondary metabolites have the ability to function as protective agents against 
pathogens such as insects, fungi and bacteria or as growth regulator molecules such 
as hormone-like substances stimulating or inhibiting cell division and 
morphogenesis. Given all these great abilities, secondary metabolites stand as 
potential anti-cancer drugs as they are able to affect cancerous cells directly or 
stimulate the tumour development or direct inhibition of cells (Kintzios & Barberaki 
2004). Examples of some anti-cancer drugs of natural origin are paclitaxel from 
Taxus brevifolia Nutt, vinblastine and vincristine from Catharanthus roseus and 
camptothecin from Camptotheca acuminata (Newman, Cragg & Snader 2003).  
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Extensive studies have been conducted to assess the role of oxidative stress and 
hence the use of antioxidants in the prevention of many disease processes that occurs 
in cancer, inflammation, atherosclerosis and age related illnesses (Fernández-Pachón 
et al. 2004; Chiang, Lo & Lu 1994; Cos et al. 1998). This has since encouraged the 
search for new natural antioxidants (Barreto et al. 2008). In the initial stage of such 
diseases, oxidative stress plays a major role. Reactive oxygen species (ROS) which is 
formed during normal metabolism have the capacity to damage proteins, lipids or 
DNA. Endogenous antioxidant defense architecture exists and is preliminarily 
responsible for preventing these damages. Nonetheless, the power of this endogenous 
system may not be adequate to combat the excessive oxidative damage, therefore it is 
imperative to have an additional supplement of external antioxidants via dietary 
source (Fernández-Pachón et al. 2004). Previous studies have also suggested that 
dietary consumption with high phenolics content may able to reduce the incidence 
rates of fatal diseases such as cancer and cardiovascular diseases (Kris-Etherton et al. 
2002; Ramarathnam et al. 1995).  
To date, there have been extensive studies on natural products compounds and 
extracts that show potent anti-angiogenic activity, in conjunction to having good 
antioxidant abilities (Cao & Cao 1999; Lamy, Gingras & Béliveau 2002; Lamy et al. 
2006). Green tea catechins and crude green tea extracts were found to inhibit both 
breast cancer cells and proliferation of endothelial cells in vitro. The green tea 
extracts has shown significant reduction in VEGF peptide expression in both cells 
with dose-dependent effect (Sartippour et al. 2002).  
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Prominent components of green tea, epigallocatechin-3-gallate (EGCG) as well 
as the crude tea extract itself were found to show specific inhibition on endothelial 
cells growth and inhibition of new microvessels growth in chorioallantoic membrane 
assay. The tea extract also showed prevention of corneal angiogenesis which had 
been pre-stimulated with VEGF (Cao & Cao 1999). EGCG also significantly 
suppressed hypoxia and serum-induced HIF-1α protein build up in human cervical 
carcinoma (HeLa) and hepatoma (Hep G2) cancer cells. Inhibition of HIF-1α caused 
significant reduction in VEGF expression in mRNA and proteins levels (Zhang et al. 
2006).  
Anthocyanidins, a type of phenolic compound has been found to cause 
downstream signalling of VEGF-R2; it also inhibits the formation of capillary-like 
tubular structures in vitro as well as inhibition of basic fibroblast growth factor-
induced vessel formation in the mouse matrigel plug assay (Lamy et al. 2006). 
Silibinin, a type of flavonoid showed suppression on tumour xenograft model via 
reduction in the neovascularisation leading to increased apoptosis. Silibinin also 
inhibited migration in HUVECs. Induction of apoptosis was observed in both 
caspase-dependent and independent mechanisms (Singh et al. 2004). Quercetin, a 
major flavonoid constituent has been reviewed extensively with antioxidant, anti-
inflammatory, cardioprotective effects as well as anti-cancer activity. It also 
exhibited significant inhibition on angiogenesis cascades such as proliferation, 
migration and tube formation of human microvascular dermal endothelial cells dose-
dependently (Mojzis et al. 2008).  
